Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionSchrodinger Inc. Common Stock (SDGR)
Fair value
Not available
ACCE price target
$21.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 28 Sept 2026, 00:00 CEST.
Price used: $23.80 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
41
out of 100
Analysts
71% buy
7 covering
P/E
0.0x
forward 0.0x
1-year return
+8.4%
Dividend yield
0.00%
Schrodinger Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Schrodinger sells physics-based molecular simulation software to drug and materials researchers, and develops its own drug candidates. Its software is used in drug discovery workflows and earns licence revenue with a 56.9% gross margin. Growth depends on software adoption and milestone payments from its pipeline. Revenue grew 7.5% but the operating margin is -70.5%, so cost discipline and pipeline progress are the questions.